Welcome to First 90 Days, a series dedicated to examining how pharma executives and other leaders are planning for success in their new roles. Today, we’re speaking to Utpal Singh, chief scientific officer at Zealand Pharma, a peptide specialist that’s caught Big Pharma’s attention.
Drugmakers looking for an edge in the booming obesity market aren’t just hunting for the next potential blockbuster. Talent is also a hot commodity, and one European biotech with mid- and late-stage obesity assets bagged a big name in the field last month.
Utpal Singh, who calls himself a “drug hunter” on LinkedIn, has leapt from Eli Lilly’s small molecule business into the chief scientific officer role at Zealand Pharma, a peptide-focused biotech with several obesity candidates in the works.
Zealand grabbed headlines mid-March when…